Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro

Molecular Medicine

Volumn 5, Issue 6, 1999, Pages 361-371

  Sakaue, Shinji ^a   Nishihira, Jun ^a   Hirokawa, Junichi ^a   Yoshimura, Haruhiko ^a   Honda, Toshiro ^a   Aoki, Kenji ^a   Tagami, Seiichi ^a   Kawakami, Yoshikazu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADIPOCYTE; ARTICLE; CELL CULTURE; CELL LEVEL; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RELEASE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 0032806620     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402125     Document Type: Article

References (36)

1. Bloom BR, Bennett B. (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82.
2. David JR. (1966) Delayed hypersensitivity in vitro: its mediation by cell free substances forms by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U.S.A. 56: 72-77.
3. Bernhagen J, Calandra T, Mitchell RA, et al. (1993) MIF is a pituitary-derived cytokine that potentiated endotoxaemia. Nature 365: 756-759.
4. Calandra T, Bernhagen J, Mitchell RA, Bucala R. (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179: 1895-1902.
5. Bacher M, Metz CN, Calandra T, et al. (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl Acad. Sci. U.S.A. 93: 7849-7854.
6. Bernhagen J, Bacher M, Calandra T, et al. (1996) An essential role for macrophage migration inhibitory factor (MIF) in the delayed-type hypersensitivity reaction. J. Exp. Med. 183: 277-282.
7. Calandra T, Bernhagen J, Metz CN, et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71.
8. Bacher M, Meinhardt A, Lan HY, et al. (1997) Macrophage migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 150: 235-246.
9. Weaber G, Calandra T, Roduit R, et al. (1997) Insulin secretion is regulated by the glucose-dependent production of islet ß cell macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U.S.A. 94: 4782-4787.
10. Hirokawa J, Sakaue S, Tagami S, el al. (1997) Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-α. Biochem. Biophys. Res. Commun. 235: 94-98.
11. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432.
12. Samad F, Yamamoto K, Loskutoff DJ. (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis Factor-α and lipopolysaccharide. J. Clin. Invest. 97: 37-46.
13. Hotamisligil GS, Shargill NS, Spiegelman BM. (1993) Adipose expression of tumor necrosis Factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-91.
14. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271: 665-668.
15. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J. Clin. Invest. 94: 1543-1549.
16. Sakai M, Nishihira J, Hibiya Y, Koyama Y, Nishi S. (1994) Glutathione binding rat liver 13k protein is the homologue of the macrophage migration inhibitory factor. Biochem. Mol. Biol. Int. 33: 439-446.
17. Nishihira J, Kuriyama T, Sakai M, Nishi S, Ohki S, Hikichi K. (1995) The structure and physicochemical properties of rat liver macrophage migration inhibitory factor. Biochim. Biophys. Acta 1247: 159-162.
18. Suzuki M, Murata E, Tanaka I, Nishihira J, Sakai M. (1994) Crystallization and a preliminary X-ray diffraction study of macrophage migration inhibitory factor from human lymphocytes. J. Mol. Biol. 265: 1141-1143.
19. Sugimoto E, Suzuki M, Nakagawa A, Tanaka I, Fujinaga M, Nishihira J. (1995) Crystallization of rat liver macrophage migration inhibitory factor for MAD analysis. J. Struct. Biol. 115: 331-334.
20. Hirokawa J, Sakaue S, Furuya Y, et al. (1998) Tumor necrosis factor-α regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3T3-L1 adipocytes. J. Biochem. 123: 733-739.
21. Suzuki H, Kanagawa H, Nishihira J. (1996) Evidence for the presence of macrophage migration inhibitory factor in murine reproductive organs and early embryos. Immunol. Lett. 51: 141-147.
22. Makita H, Nishimura M, Miyamoto K, et al. (1998) Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am. J. Respir. Crit. Care Med. 158: 573-579.
23. Rodbell M. (1964) Metabolism of isolated fat cells. I. Effect of hormones on glucose metabolism and lipolysis. J. Biol. Chem. 239: 375-380.
24. Chen L, Alam T, Johnson J, Hughes S, Newgard CB, Unger RH. (1990) Regulation of ß-cell glucose transporter gene expression. Proc. Natl. Acad. Sci. U.S.A. 87: 4088-4092.
25. Suzuki K, Kono T. (1980) Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc. Natl. Acad. Sci. U.S.A. 77: 2542-2545.
26. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z. (1981) A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 30: 1045-1050.
27. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. (1992) Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima fatty (OLETF) strain. Diabetes 41: 1422-1428.
28. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. (1995) Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
29. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. (1994) Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl. Acad. Sci. U.S.A. 91: 4854-4858.
30. Ishida K, Mizuno A, Murakami T, Shima K. (1996) Obesity is necessary but not sufficient for the development of diabetes mellitus. Metabolism 45: 1288-1295.
31. Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H. (1998) Pioglitazone time-dependently reduces tumor necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41: 257-264.
32. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J. Biol. Chem. 270: 12953-12956.
33. Tontonoz P, Hu E, Spiegelman BM. (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156.
34. Hallakou S, Doare L, Foufelle F, et al. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46: 1393-1399.
35. Sugiyama Y, Shimura Y, Ikeda I. (1990) Effect of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforschung 40; 436-440.
36. Szalkowski D, White-Carrington S, Berger J, Zhang B. (1995) Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136: 1474-1481.